The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
Open accessAbstract
Apolipoprotein (apo) E4, a 299-aa protein and a major risk factor for Alzheimer's disease, can be cleaved to generate C-terminal-truncated fragments that cause neurotoxicity in vitro and neurodegeneration and behavioral deficits in transgenic mice. To investigate this neurotoxicity, we expressed apoE4 with C- or N-terminal truncations or mutations in transfected Neuro-2a cells. ApoE4 (1-272) was neurotoxic, but full-length apoE4(1-299) and apoE4(1-240) were not, suggesting that the lipid-binding region (amino acids 241-272) mediates the neurotoxicity and that amino acids 273-299 are protective. A quadruple mutation in the lipid-binding region (I250A, F257A, W264R, and V269A) abolished the neurotoxicity of apoE4(1-272), and single mutations in the region of amino acids 273-299 (L279Q, K282A, or Q284A) made full-length apoE4 neurotoxic. Immunofluorescence staining showed that apoE4(1-272) formed filamentous inclusions containing phosphorylated tau in some cells and interacted with mitochondria in others, leading to mitochondrial dysfunction as determined by MitoTracker staining and flow cytometry. ApoE4(241-272) did not cause mitochondrial dysfunction or neurotoxicity, suggesting that the lipid-binding region alone is insufficient for neurotoxicity. Truncation of N-terminal sequences (amino acids 1-170) containing the receptor-binding region (amino acids 135-150) and triple mutations within that region (R142A, K146A, and R147A) abolished the mitochondrial interaction and neurotoxicity of apoE4(1-272). Further analysis showed that the receptor-binding region is required for escape from the secretory pathway and that the lipid-binding region mediates mitochondrial interaction. Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE4 increases the sensitivity of cells to oxidative stress”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the generation of a toxic C-terminal fragment of apoE4 that can directly target electron transport chain (ETC) complexes in the mitochondria25–27”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the molecular level, ApoE4 has been associated with aggravated AD neuropathology, enhanced neuroinflammation, deregulated lipid metabolism, mitochondrial dysfunction, and impaired synaptic plasticity (Nagy et al., 1995;Chang et al., 2005;Rapp et al., 2006;Klein et al., 2010;Rodriguez et al., 2014).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Chang et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“expression of fragments containing this domain in N2a cells results in neurotoxicity [17]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and cause mitochondrial fragmentation [10, 17, 20]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest apoE4 fragment, apoE4(1–272), interacts directly with mitochondria to reduce mitochondrial membrane potential”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurons, apoE4 is associated with impaired mitochondrial respiration”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies on the trafficking of APOE have also suggested that the cleaved C-terminus of APOE can exist in the cytoplasm and associate with mitochondria in neurons (Chang et al., 2005).”
From APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size (2024) · cites this paper as Chang et al., 2005
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and in higher levels than in age- and sex-matched controls [29].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE4 largest fragment (1–272 aa) was shown to directly interact with mitochondria, which leads to a decrease in Δψm and mitochondrial fragmentation [26,29,73].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Limited data suggest that a particular fragment of apoE (1–272 amino acids) can translocate to cytosol and interacts with cytoskeletal proteins (Chang et al., 2005).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Chang et al., 2005
The cited source says what the claim attributes to it.
In the citing paper
“These and other findings suggest that not all apoE4 forms found in the brains of AD patients are equally bioactive and that specific apoE4 forms may be involved in processes associated with AD pathogenesis (10, 14 -17).”
From Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4 (2014) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“In vitro studies have shown that fragments of APOE, which are more abundant with APOE4 than with APOE3, can cause neuronal mitochondrial dysfunction165,166.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [165]
The cited source says what the claim attributes to it.
In the citing paper
“apoE4 (1-272) fragment appears to interact directly with mitochondria, resulting in mitochondrial dysfunction and neurotoxicity [13]”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Available literature also shows that apoE4 (1-272) fragments can directly interact with mitochondria, causing mitochondrial dysfunction and neurotoxicity [13].”
From APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The resulting apoE fragments escape the secretory pathway into the cytosol”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“and neurotoxicity [10, 17–19, 34, 35]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Although apoE fragments interact directly with mitochondria and disrupt their function [17, 20]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The interaction of apoE4 fragments with mitochondria is dependent on the apoE lipid-binding domain”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“where they engage in abnormal interactions that lead to neurodegeneration [17–19]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“some studies in N2a cells demonstrated that ApoE4 N-terminal fragments (1–272 aa) interact with mitochondria and may possibly impact on mitochondrial function and cell viability [29]”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Both regions are thought to be critical for ApoE4 fragment-related neurotoxicity and mitochondrial impairment, rather than full-length protein [29,31].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“In vitro studies in N2a cells showed that ApoE4 fragments (aa 1–272) interact with mitochondria and cause mitochondrial dysfunction and neurotoxicity [29].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, more recent data suggests the possibility that a fragment of apoE4 (1–272 amino acids), but not full-length apoE4, escapes the secretory pathway, translocates to the cytosolic compartment, and interacts with cytoskeletal components, including tau and neurofilament (Chang et al., 2005).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Chang et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“decreased neurite outgrowth”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“The APOE gene product, interestingly, also appears to influence mitochondrial function [164-167].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Self-citationCellular uptake of the tat protein from human immunodeficiency virus
Frankel, A. D., & Pabo, C. O. (1988) · Cell · doi:10.1016/0092-8674(88)90263-2 · Cited by 2,782
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A. L., Vocero-Akbani, A. M., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,418
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Self-citationGreen, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,551
Berridge, M. V., & Tan, A. S. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1311 · Cited by 1,443
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Flagged first, then by citations
1 of the 73 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Wisniewski, T., Castaño, E. M., Golabek, A., Vogel, T. & Frangione, B. (1994) Am. J. Pathol. 145, 1030-1035.7977635
Cited by
Sorted by citations
Items 201–300 of 321
He, K., Nie, L., Zhou, Q., Rahman, S. U., Liu, J., Yang, X., & Li, S. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00136 · Cited by 24
Faraji, P., Kühn, H., & Ahmadian, S. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02224-4 · Cited by 25
VPO1 Mediates ApoE Oxidation and Impairs the Clearance of Plasma Lipids
Yang, Y., Cao, Z., Tian, L., Garvey, W. T., & Cheng, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057571 · Cited by 23
Roses, A. D., Akkari, P. A., Chiba‐Falek, O., Lutz, M. W., Gottschalk, W. K., Saunders, A. M., Saul, B., Sundseth, S. S., & Burns, D. K. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1133586 · Cited by 23
Lysosomal proteomics reveals mechanisms of neuronal APOE4-associated lysosomal dysfunction
Krogsaeter, E., McKetney, J., Valiente‐Banuet, L., Marquez, A., Willis, A., Cakir, Z., Stevenson, E. J., Jang, G. Μ., Rao, A. T., Li, E., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2576613 · Cited by 22
Self-citationDifferent quantitative EEG alterations induced by TBI among patients with different APOE genotypes
Jiang, L., Yin, X.-H., Yin, C., Zhou, S., Dān, W., & Sun, X. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.10.011 · Cited by 22
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01020-9 · Cited by 24
Pisani, F., Pisani, V., Arcangeli, F., Harding, A., & Singhrao, S. K. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20116049 · Cited by 21
Ning, Z., Liu, Y., Wan, M., Zuo, Y., Chen, S., Shi, Z., Xu, Y., Li, H., Ko, H., Zhang, J., et al. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00600-x · Cited by 20
Alzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 19
A Review of ApoE4 Interference Targeting Mitophagy Molecular Pathways for Alzheimer's Disease
Chen, H., Chen, F., Jiang, Y., Zhang, L., Hu, G., Sun, F., Zhang, M., Ji, Y., Chen, Y., Che, G., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881239 · Cited by 19
Vidal, C., & Li, Z. (2021) · Cells · doi:10.3390/cells10030546 · Cited by 20
Gamarra, D., Elcoroaristizabal, X., Martínez, M. F., & de Pancorbo, M. M. (2015) · Disease Markers · doi:10.1155/2015/746329 · Cited by 18
Slot, R. E. R., Kester, M. I., van Harten, A. C., Jongbloed, W., Bouwman, F. H., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Veerhuis, R. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.017 · Cited by 18
Liou, C., Chen, S., Lin, T., Tsai, M., & Chang, C. (2021) · Antioxidants · doi:10.3390/antiox10121971 · Cited by 17
Iurescia, S., Fioretti, D. P., Mangialasche, F., & Rinaldi, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100009 · Cited by 18
Mitochondria Profoundly Influence Apolipoprotein E Biology
Gabrielli, A. P., Weidling, I. W., Ranjan, A., Wang, X., Novikova, L., Chowdhury, S. R., Menta, B. W., Berkowicz, A., Wilkins, H., Peterson, K. R., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221177 · Cited by 16
Wang, M., & Turko, I. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061498 · Cited by 16
Tabuena, D. R., Jang, S.-S., Grone, B. P., Yip, O., Jones, E. A. A., Blumenfeld, J. R., Liang, Z., Mann, R. S., Li, Y., Necula, D., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01096-0 · Cited by 17
Self-citationAltering Mitochondrial Dysfunction as an Approach to Treating Alzheimer’s Disease
Colca, J. R., & Feinstein, D. L. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00005-2 · Cited by 14
APOE ɛ4 allele and TOMM40‐APOC1 variants jointly contribute to survival to older ages
Kulminski, A. M., Jain‐Washburn, E., Philipp, I., He, L., Loika, Y., Loiko, E., Bagley, O., Ukraintseva, S. V., Yashin, A. I., Arbeev, K. G., et al. (2022) · Aging Cell · doi:10.1111/acel.13730 · Cited by 14
Belinson, H., & Michaelson, D. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1065 · Cited by 15
Wang, H.-Y., Trocmé, C., Stucky, A., Shah, S. M., Kvasic, J., Khan, A., Morain, P., Guignot, I., Bouguen, E., Deschet, K., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0280-8 · Cited by 14
RetractedDafnis, I., Argyri, L., & Chroni, A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.10.026 · Cited by 12
Effects of Microglial Cytokines on Alzheimer’s Disease-Related Phenomena
Ji, Y., Wang, X., Kalicki, C. H., Menta, B. W., Baumgardner, M., Koppel, S. J., Weidling, I. W., Ortiz, J. P., Wilkins, H., & Swerdlow, R. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180820 · Cited by 12
Dose, J., Nebel, A., Piegholdt, S., Rimbach, G. H., & Huebbe, P. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.031 · Cited by 11
Cai, M., & Yang, E. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606480 · Cited by 11
Yang, J., Zhao, H., & Qu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117144 · Cited by 11
Beresford‐Webb, J., McAllister, C. J., Sleigh, A., Walpert, M., Holland, A. J., & Zaman, S. H. (2025) · Brain Sciences · doi:10.3390/brainsci15020130 · Cited by 10
Apolipoprotein E receptor pathways in Alzheimer disease
Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 10
Singh, L. N., Kao, S.-H., & Wallace, D. C. (2021) · Cells · doi:10.3390/cells10123460 · Cited by 10
Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele
Ji, X., Peng, X., Tang, H., Pan, H., Wang, W. D., Wu, J., Chen, J., & Wei, N. (2023) · Brain Pathology · doi:10.1111/bpa.13208 · Cited by 9
Epigenomics of Alzheimer’s Disease
Bennett, D. A., Yu, L., Yang, J., Klein, H., & Jager, P. L. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800802-7.00009-5 · Cited by 9
The heterogeneity among subgroups of haplogroup J influencing Alzheimer’s disease risk
Liu, H.-C., Zhang, Y., Zhao, H., Du, Y., & Liu, X. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.02.003 · Cited by 9
Li, W., Li, Y., Qiu, Q., Sun, L., Yue, L., Li, X., & Xiao, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00827 · Cited by 9
Chen, X., Wei, Z., Wang, T., Zhang, Z.-L., Wang, Y., Heckman, M. G., Diehl, N. N., Zhang, Y., Xu, H., & Bu, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143157 · Cited by 8
Gupta, A. K., Pokhriyal, R., Das, U., Khan, M. I., Kumar, D. R., Gupta, R., Chadda, R. K., Ramachandran, R., Goyal, V., Tripathi, M., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s205550 · Cited by 8
de Brito-Marques, P. R., Rocha‐Filho, P. A. S., Dellalibera, E., Muniz, M. T. C., & Correia, C. D. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05923-4 · Cited by 7
A Mitochondrial DNA Haplogroup Defines Patterns of Five-Year Cognitive Change
Watts, A. S., Chalise, P., Hu, J., Hui, D., Pa, J., Andrews, S. J., Michaelis, E. K., & Swerdlow, R. H. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220298 · Cited by 7
Frisardi, V. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111568 · Cited by 7
Roses, A. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.288 · Cited by 7
Wallace, D. C., Lott, M. T., & Procaccio, V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00013-6 · Cited by 8
Mitochondria in Neurodegeneration
Swerdlow, R. H. (2011) · Advances in neurobiology · doi:10.1007/978-1-4614-1788-0_30 · Cited by 7
Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism
Lindqvist, D., Prokopenko, I., Londos, E., Middleton, L. T., & Hansson, O. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150693 · Cited by 7
Molecular genetics of early-onset Alzheimer's disease and frontotemporal lobar degeneration
Krüger, J. (2010) · Cited by 7
Bello-Corral, L., Seco‐Calvo, J., Fresno, Á. M., González, A. I., Llorente, A. M., Fernández‐Lázaro, D., & Sánchez-Valdeón, L. (2024) · Medicina · doi:10.3390/medicina60121941 · Cited by 6
Cardoso, R., Lemos, C., Oliveiros, B., Almeida, M. R., Baldeiras, I., Pereira, C., SANTOS, A. C. D. S., Duro, D., Vieira, D., Santana, I. J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200556 · Cited by 6
Fragmentation of brain apolipoprotein E (ApoE) and its relevance in Alzheimer's disease
Asiamah, E. A., Feng, B., Guo, R., Zhang, W., He, J., Kong, D., Dong, T., Ma, J., & Cui, H. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0115 · Cited by 6
Apolipoprotein E and Amyloid-β-Independent Mechanisms in Alzheimer’s Disease
Kanekiyo, T., & Bu, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00006-1 · Cited by 6
Huang, Y., & Mahley, R. W. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.12.006 · Cited by 6
Self-citationMitochondrial dysfunction in Alzheimer's disease and related sex differences
Misrani, A., Ngwa, C., & Liu, F. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1761702 · Cited by 5
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 6
Harasta, A. E., & Ittner, L. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_1 · Cited by 5
Jamerlan, A., Dominguez, J. C., Ligsay, A. D., Youn, Y. C., An, S. S. A., & Kim, S. (2019) · Molecular & Cellular Toxicology · doi:10.1007/s13273-019-0039-3 · Cited by 5
Johnson, C. N., Evans, M. R., Blankenship, A. E., John, C. S., Rekowski, M. J., Washburn, M. P., Phan, A. V., Gouvion, C. M., Haeri, M., Swerdlow, R. H., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106916 · Cited by 6
Uwisengeyimana, J. D. D., Wang, Y., Nguchu, B. A., Wang, X., & Qiu, B. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120435 · Cited by 4
Johnson, C. N., McCoin, C. S., Kueck, P. J., Hawley, A. G., John, C. S., Thyfault, J. P., Swerdlow, R. H., Geiger, P. C., & Morris, J. K. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221192 · Cited by 4
The Dynamic SUMOylation Changes and Their Potential Role in the Senescence of APOE4 Mice
Xu, Y., Cai, W., Sang, S., Cheng, X., Jin, B., Zhao, X., & Zhong, C. (2023) · Biomedicines · doi:10.3390/biomedicines12010016 · Cited by 4
Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide
Crutcher, K. A., Lilley, H. N., Anthony, S., Zhou, W., & Narayanaswami, V. (2009) · Brain Research · doi:10.1016/j.brainres.2009.10.021 · Cited by 5
Chromosomal DNA damage in APOE ɛ4 carriers and noncarriers does not appear to be different
Chua, A., Thomas, P., Clifton, P. M., & Fenech, M. F. (2015) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21949 · Cited by 4
Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?
Caselli, R. J. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24768 · Cited by 4
Müller Glial Kir4.1 Channel Dysfunction in APOE4 ‐ KI Model of Alzheimer's Disease
Abhyankar, S. D., Xiao, Y., Mahajan, N. S., Luo, Q., Cummins, T., Oblak, A. L., Lamb, B. T., Corson, T. W., & Bhatwadekar, A. D. (2026) · Glia · doi:10.1002/glia.70119 · Cited by 3
Kimura, A., Hata, S., & Suzuki, T. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.017 · Cited by 3
Campos, J. (2013) · Journal of Antivirals & Antiretrovirals · doi:10.4172/jaa.s10-003 · Cited by 3
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Jiang, L., Sun, X., Xie, Y., Dān, W., Xia, Y., & Xu, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135392 · Cited by 2
RetractedNazareth, M., Duck, S. A., Fassinger, A., Elmore, G., Pinto, C., Nugent, M., Pierre, M. S., Lechner, C., Jantzie, L. L., Northington, F. J., et al. (2025) · Developmental Neuroscience · doi:10.1159/000548432 · Cited by 2
A Nanobody-Based Toolbox to Probe ApoE4 in the Secretory Pathway and Cytosol
Vandevelde, L., Zwaenepoel, O., Bruycker, E. D., Ranson, M., Stichel, C. V., Matthys, C., & Gettemans, J. (2026) · Cells · doi:10.3390/cells15050479 · Cited by 2
Molecular etiopathogenesis of neurodegenerative diseases
Divya, D., Thekkekkara, D., Sai, T. E., Ramakrishna, D., Manjula, S. N., & Goswami, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00002-7 · Cited by 2
The Amyloid _-Protein and Alzheimer's Disease
Teplow, D. B., Yang, M., Roychaudhuri, R., Pang, E. S., Huynh, T. V., Chen, M., & Beroukhim, S. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-2 · Cited by 2
Research Progress of Mitophagy in Alzheimer's Disease
Yao, J., Kan, B., Dong, Z., & Tang, Z. (2023) · Current Alzheimer Research · doi:10.2174/0115672050300063240305074310 · Cited by 2
Mitochondria in Alzheimer disease : regulatory mechanisms and cell death
Hedskog, L. (2012) · Figshare · Cited by 2
Neuron-specific susceptibility to apolipoprotein E4
Belinson, H., Dolev, I., & Michaelson, D. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.027 · Cited by 2
Perturbed Brain Energy Metabolism in Alzheimer’s Disease and Diabetes
Wu, L. (2017) · KU ScholarWorks (University of Kansas) · Cited by 2
Roland, N. J., Zigmond, J. W., Manganaro, J. E., Estrella, L. D., & Stauch, K. L. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106125 · Cited by 1
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
Self-citationKehmeier, M. N., Famiano, A., Cullen, A. E., Leonhardt, T., Ferguson, S. J., Snyder, M., McCurdy, C. E., Tyrrell, D. J., Alkayed, N. J., & Walker, A. E. (2026) · The Journal of Physiology · doi:10.1113/jp290852 · Cited by 2
Trial News: Woes, New Approaches
Landhuis, E. W.-Y., & Fagan, T. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1428 · Cited by 1
Lardizabal, J. J. T. (2010) · Summit (Simon Fraser University) · Cited by 1
Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging
Kwon, O. D. (2016) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2016.15.3.61 · Cited by 1
Autophagy and Proteostasis: A Unifying Theory of Neurodegenerative Disease
Novack, J. P. (2017) · Journal of Restorative Medicine · doi:10.14200/jrm.2017.6.0102 · Cited by 1
Qiu, S., & Weeber, E. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-76761-1_12 · Cited by 1
Neurogenesis in the adult brain, gene networks, and Alzheimer's Disease
Horgusluoglu, E. (2017) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1972 · Cited by 1
APOE4 disrupts the central dogma by arresting neuronal proteome dynamicsPreprint
Krogsaeter, E., McKetney, J., Li, L., Liu, I., Richards, A., Subramanyam, V., Yin, K., Gordon, M., Mairal, P. B., Stevenson, E. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.15.738801 · Cited by 1
Self-citationManotas, M. R. (2009) · Gredos (University of Salamanca) · doi:10.14201/gredos.76537
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328
Huang, R. Y.-C. (2012) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7ft8j23
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Genetic Susceptibility in Alzheimer’s Disease and the Role of Lipid Metabolism
Miller, K. H. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
The Proteolysis of Apolipoprotein E in Alzheimer's Disease
Love, J. E. (2016) · ScholarWorks (Boise State University)
Genetic Basis of Health Disparity
Kwabi‐Addo, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-55865-3_2
AXL receptor tyrosine kinase regulates Apolipoprotein E expression
Zhao, W. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0372324
Modelling the neurobiology of Alzheimer’s disease in vitro
Muñoz, S. S. (2019) · Research Online (University of Wollongong)
The interactive impact of omega-3 fatty acids, APOE genotype and sex hormones on cognition
Pontifex, M. G. (2020) · UEA Digital Repository (University of East Anglia)
Lambert, J. (2006) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.30576.487883
Genetic Determinants of Human Longevity
Dato, S., Soerensen, M., & Rose, G. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-679-6
The Convergence of Intelligence and LongevityPreprint
Gualtieri, C. (2024) · Qeios · doi:10.32388/wvwb0l
Regulation of glial ApoE secretion by the mevalonate pathway is independent of ApoE isoform
Milstein, J. L., Kulas, J. A., Kamal, A., Lo, A. B., & Ferris, H. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251317732
Metadata
- Authors
- Chang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y.
- Affiliations
- University of California, San Francisco (US)
- Gladstone Institutes (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-12-12
- Volume
- 102
- Issue
- 51
- Pages
- 18694-18699
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1311737
- OpenAlex
- W2022943683
- Cited by
- 319
- References
- 73
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 15 · 2023: 16 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 21 · 2018: 13 · 2017: 14 · 2016: 18 · 2015: 10 · 2014: 15 · 2013: 19 · 2012: 18
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Institutes of Health (AG‐022074)
- National Institute on Aging (P01AG022074)
- National Heart, Lung, and Blood Institute (R01 HL37063, R01HL037063)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- APOE ε4, neurotoxicity, mitochondrial dysfunction, receptor-binding region, Alzheimer's disease, tau phosphorylation, N2a cells, transgenic mice
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Cytoskeleton, Lipids, Mitochondria, Mutation, Neurons, Peptide Fragments, Receptors, Lipoprotein, Cell Line, Tumor, Mice, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
